Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Antineoplastic agents >  Antimetabolites, Antineoplastic >  1-beta-D-Arabinofuranosylcytosine hydrochloride

1-beta-D-Arabinofuranosylcytosine hydrochloride

Basic information Safety Supplier Related

1-beta-D-Arabinofuranosylcytosine hydrochloride Basic information

Product Name:
1-beta-D-Arabinofuranosylcytosine hydrochloride
Synonyms:
  • 4-amino-1-[3,4-dihydroxy-5-(hydroxymethyl)-2-tetrahydrofuranyl]-2-pyrimidinone
  • 4-amino-1-[3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one
  • 4-amino-1-[3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one
  • Cytosine-beta-D-arabinofuranose hydrochloride
  • -D-arabinofuranoside hydrochloride
  • 4-Amino-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-
  • arabinosylcytosinehydrochloride
  • ara-chydrochloride
CAS:
69-74-9
MF:
C9H14ClN3O5
MW:
279.68
EINECS:
200-713-9
Product Categories:
  • Pyridines, Pyrimidines, Purines and Pteredines
  • 69-74-9
Mol File:
69-74-9.mol
More
Less

1-beta-D-Arabinofuranosylcytosine hydrochloride Chemical Properties

Melting point:
197-198 °C(lit.)
storage temp. 
2-8°C
solubility 
insoluble in EtOH; ≥14.2 mg/mL in DMSO; ≥64.2 mg/mL in H2O
form 
crystalline
color 
White to off-white
Stability:
Stable. Combustible. Incompatible with strong oxidizing agents.
InChIKey
KCURWTAZOZXKSJ-XKIMMOKZSA-N
CAS DataBase Reference
69-74-9(CAS DataBase Reference)
EPA Substance Registry System
Cytarabine hydrochloride (69-74-9)
More
Less

Safety Information

Hazard Codes 
Xn
Risk Statements 
36-43-63
Safety Statements 
26-36/37
WGK Germany 
3
RTECS 
HA5500000
HazardClass 
IRRITANT
HS Code 
29389090
Toxicity
LD50 oral in rat: > 3200mg/kg

MSDS

More
Less

1-beta-D-Arabinofuranosylcytosine hydrochloride Usage And Synthesis

Description

Cytosine beta-D-arabinofuranoside Hydrochloride is the salt form of Cytarabine, which is a selective inhibitor of DNA synthesis and is used as an antineoplastic and antiviral. Cytosine beta-D-arabinofuranoside Hydrochloride is used in chemotherapy for the treatment of white blood cells cancers such as acute myeloid leukemia (AML) and non-Hodgkin lymphoma.

Chemical Properties

Crystalline

Originator

Cytosar,Upjohn,US,1969

Uses

Interferes with the synthesis of DNA

Uses

Antiviral.

Manufacturing Process

(A) Preparation of 1- (2,3,5-Tri-O-Acetyl-β-D-Arabinofuranosyl)-4-Thiouracil: A mixture of 1.85 g (5.0 mmol) of 1-(2,3,5-tri-O-acetyl-β-arabinofuranosyl) uracil, 1.23 g (5.55 mmol) of phosphorus pentasulfide, and 30 ml of pyridine was heated under gentle reflux for 2.5 hours with exclusion of moisture. The reaction mixture was cooled, and the supernatant solution was transferred by means of a pipette into a mixture of crushed ice and water. The reaction flask was washed twice with pyridine, and these washings were added to the icewater mixture. This mixture was kept at about 25°C until the ice had melted, and was then stored at 0°C for one hour. A pale yellow precipitate that formed was collected on a filter, washed with ice-water, and dried in air.
This material was triturated with chloroform, and the chloroform mixture was filtered. A small amount of undissolved material collected on the filter and it was washed with chloroform. The chloroform solution (filtrate plus washings) was washed three times with ice-water, twice with ice-cold 3 N sulfuric acid, twice with ice-cold saturated aqueous sodium bicarbonate solution, twice with ice-water, and then dried over anhydrous sodium sulfate. The chloroform was removed under reduced pressure at a bath temperature of about 40°C, leaving a yellow, somewhat gummy residue. This yellow residue was dissolved in absolute methanol which was then evaporated at reduced pressure at about 40°C, and the residue was then held for 2 hours at 0.5 to 2.0 mm pressure and a bath temperature of about 50°C. There was thus obtained 1.69 g of 1- (2,3,5-tri-O-acetyl-β-D-arabinofuranosyl)-4-thiouracil.
(B) Preparation of 1-β-D-Arabinofuranosylcytosine: In a glass liner, a mixture of 1.16 g (3.0 mmol) of 1-(2,3,5-tri-O-acetyl-β-D-arabinofuranosyl)-4- thiouracil prepared in (A) and about 60 ml of absolute methanol which had been saturated with anhydrous ammonia at 0°C was heated in a steel bomb at 98° to 105°C for 35 hours. After cooling to about 25°C and venting the bomb, the dark solution was filtered into a round-bottom flask. The methanol and excess ammonia were then removed under reduced pressure at about 25°C. The residual syrup was dissolved in absolute methanol, and the methanol was removed under reduced pressure at a bath temperature of about 40°C. This procedure of dissolving in absolute methanol and removing the solvent was repeated, and the residue was held under reduced pressure at a bath temperature of 45°C for 12 hours.
The resulting semisolid was triturated thoroughly with absolute methanol, and the resulting suspension was chilled at 0°C. A pale tan solid that separated was collected on a filter and washed repeatedly with methanol. After washing with anhydrous ether, there was obtained 430 mg of 1-β-Darabinofuranosylcytosine.
(C) Preparation of 1-β-D-Arabinofuranosylcytosine Hydrochloride: The absolute methanolic filtrate obtained after triturating and filtering the 1-β-Darabinofuranosylcytosine in (B) above was warmed and stirred with decolorizing charcoal. The mixture was filtered through a bed of filter aid, and the filter bed was washed repeatedly with absolute methanol. The combined filtrate and washings were pale yellow. The solution was diluted to faint cloudiness with anhydrous ether, and an excess of anhydrous hydrogen chloride was introduced. Crystallization began at about 25°C and further crystallization was induced by chilling at 0°C for 14 hours. The crystalline product was collected on a filter, washed with anhydrous ether, and dried in air. There was thus obtained 180 mg of pale yellow 1-β-Darabinofuranosylcytosine hydrochloride melting at 186° to 189°C.
The pale yellow product was dissolved in warm, absolute methanol, and the solution after mixing with decolorizing charcoal was filtered through a bed of filter aid. The filter bed was washed with warm absolute methanol, and the combined methanolic filtrate and washings were warmed and diluted with anhydrous ether to incipient crystallization. The methanol-ether mixture was kept at about 25°C for about 1 hour and then chilled, first at 0°C, and then at -20°C. The resulting colorless needles were collected on a filter, washed with anhydrous ether, and dried at 85°C, yielding 100 mg of 1-β-Darabinofuranosylcytosine hydrochloride having a melting point of 186° to 188°C.

Therapeutic Function

Cancer chemotherapy

General Description

Crystals (from aqueous ethanol) or fluffy white powder.

Air & Water Reactions

Water soluble. Hydrolysis occurs readily, especially with acid.

Reactivity Profile

1-beta-D-Arabinofuranosylcytosine hydrochloride undergoes decomposition in acidic solutions.

Fire Hazard

Flash point data for 1-beta-D-Arabinofuranosylcytosine hydrochloride are not available; however, 1-beta-D-Arabinofuranosylcytosine hydrochloride is probably combustible.

Biological Activity

cytarabine hydrochloride is an effective drug in the treatment of cancers of white blood cells [1].cytarabine hydrochloride is a dxoxycytidine (dc) analogue. cytarabine hydrochloride has been found to be phosphorylated into a triphophate form, and thus compete with dctp for incorporation into dna. cytarabine hydrochloride has reported to incorporate into dna and block dna synthesis by inhibiting the function of dna and rna polymerases. in addition, incorporated has shown a growth inhibition dose-dependent curve using acute myelogenous leukemia (aml) in a growth inhibition assay with ic50 values of 16nm,103μm and 223μm for ccrf-cem, cem/arac8c and cem/dck-cell lines, respectively. moreover, cytarabine hydrochloride has been exhibited to retrovirally transducer rat leukemic ka cells by wst-1 assay with ic50 values of 0.69μm,1.73μm and 0.037μm for ka, ka/gfp and ka/wt, respectively [1,2].

Biochem/physiol Actions

Ara-C is phosphorylated to Ara-CTP and is incorporatee into DNA. It inhibits DNA replication by forming cleavage complexes with topoisomerase I resulting in DNA fragmentation, and ultimately induces apoptosis via the PKC signaling pathway. Does not inhibit RNA synthesis. Anti-leukemia agent.

Safety Profile

Poison by intravenous route.Moderately toxic by intraperitoneal and subcutaneousroutes. Experimental reproductive effects. A human eyeirritant. Mutation data reported. When heated todecomposition it emits very toxic fumes of NOx and HCl.

References

[1] tobias sc1, borch rf.synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. mol pharm. 2004 mar-apr; 1(2):112-6.
[2] veuger mj1, heemskerk mh, honders mw, willemze r, barge rm.functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells. blood. 2002 feb 15; 99(4):1373-80.

1-beta-D-Arabinofuranosylcytosine hydrochloride Preparation Products And Raw materials

Raw materials

1-beta-D-Arabinofuranosylcytosine hydrochlorideSupplier

Jiangsu Xinderui Pharmaceutical Technology Co., Ltd Gold
Tel
0518-80639699 19852363252
Email
xutangyan@xdrpharm.com
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
Meryer (Shanghai) Chemical Technology Co., Ltd.
Tel
021-61259108 18621169109
Email
market03@meryer.com
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801 18930552037
Email
3bsc@sina.com
future industrial shanghai co., ltd
Tel
400-0066400 13621662912
Email
sales@jonln.com